18 and older, any sex, with Advanced Lymphoma or Advanced Malignant Solid Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Overall Response Rate (ORR)Primary· Tumor assessments occurred at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration
Overall response rate was defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) among all eligible and treated patients. Best overall response was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. The 90% two-sided binomial exact confidence interval was calculated for ORR.
Group
Value
95% CI
Treatment (Taselisib)
0
NA – NA
6-Month Progression-free Survival (PFS) RateSecondary· Assessed at baseline, then every 2 cycles for the first 26 cycles, and every 3 cycles thereafter until disease progression, up to 3 years post registration, from which 6-month PFS is determined
PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. The 6-month PFS rate was estimated using the Kaplan-Meier method which can provide a point estimate for any specific time point. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients.
Group
Value
95% CI
Treatment (Taselisib)
19.9
12.0 – 29.3
Progression-free Survival (PFS)Secondary· Assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration
PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients.
Group
Value
95% CI
Treatment (Taselisib)
3.1
1.8 – 3.7
Adverse events — posted to ClinicalTrials.gov
Time frame: Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Treatment (Taselisib)
Serious: 23/66 (35%)
Deaths: 66/70
Serious adverse events (24 terms)
Reaction
System
Treatment (Taselisib)
Diarrhea
Gastrointestinal disorders
—
Lung infection
Infections and infestations
—
Hyperglycemia
Metabolism and nutrition disorders
—
Hyponatremia
Metabolism and nutrition disorders
—
Nausea
Gastrointestinal disorders
—
Dehydration
Metabolism and nutrition disorders
—
Thromboembolic event
Vascular disorders
—
Fatigue
General disorders
—
Sudden death NOS
General disorders
—
Abdominal pain
Gastrointestinal disorders
—
Colitis
Gastrointestinal disorders
—
Dysphagia
Gastrointestinal disorders
—
Mucositis oral
Gastrointestinal disorders
—
Vomiting
Gastrointestinal disorders
—
Urinary tract infection
Infections and infestations
—
Aspartate aminotransferase increased
Investigations
—
Blood bilirubin increased
Investigations
—
Weight loss
Investigations
—
Anorexia
Metabolism and nutrition disorders
—
Hypokalemia
Metabolism and nutrition disorders
—
Neoplasms benign, malignant and unspecified (incl cysts and
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation. Taselisib may stop the growth of cancer cells by blocking PIK3CA, a protein that may be needed for cell growth. Researchers hope to learn if taselisib will shrink this type of cancer or stop its growth.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
NCT02465060 — Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M
· Phase 2
· active not recruiting
NCT02340221 — A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cance
· Phase 3
· terminated
NCT02273973 — A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LOR
· Phase 2
· completed
NCT02154490 — Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
· completed
Other recruiting trials for Advanced Lymphoma
Currently open trials in the same condition.
NCT06223542 — Studying TAK-243 in Patients With Advanced Cancer
· Phase 1
· recruiting
NCT05969860 — At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
· Phase 2
· recruiting
NCT05833893 — Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
· Phase 2
· recruiting
NCT05279300 — A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
· Phase 1
· recruiting
NCT06400251 — Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)
· Phase 2
· active not recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem
· Phase 1, PHASE2
· recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem
· Phase 2, PHASE3
· not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa
· Phase 2
· recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After
· Phase 1
· not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 18 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04439175.